Why the study?
Does intravenous canrenoate exhibit mineralocorticoid blocking activity and affect hemodynamics in normal subjects?
Does intravenous canrenoate exhibit mineralocorticoid blocking activity and affect hemodynamics in normal subjects?
Intravenous canrenoate demonstrates mineralocorticoid blocking activity similar to spironolactone, with its primary advantage being the capability for parenteral administration.
Answers are grounded in this paper and cite their sources.
May enable IV mineralocorticoid blockade without hemodynamic effects; hypothesis-generating and should not yet change practice.
Canrenoate, which has mineralocorticoid blocking activity, was evaluated in 3 normal subiects. The drug was administered by intravenous iniection twice daily for 7 days after 3 days of placebo. Loss of body weight and changes in serum and urine electrolytes were consistent with mineralocorticoid blocking activity. Canrenoate did not appear to have any effect on arterial blood pressure or cardiac output. A small increase in resting heart rate was demonstrated in 2 of the 3 patients, but this was thought to be secondary to volume depletion due to a diuretic action. A transient cardiac arrhythmia was noted in one sub;ect and was unexplained on the basis of serum electrolytes or plasma drug level. The only advantage of canrenoate over spironolactone appeared to be the parenteral administration.
No takes yet. Share an insight, caveat, or question.
Mroczek et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: